Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.

Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...

BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline

Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines tha...

Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023

Clovis Oncology Inc. shares CLVS, -71.62% plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company ...

The Bulls Still Own This Market. But Cracks Are Starting to Show.

Text size Riskier and more speculative pockets of the market have led the rally, which has coincided with a decline in bond yields. NYSE If it looks like a bull market and acts like a bull market, it’...

If this stock market is shaping up like 2008, here’s where we could be headed next, says strategist

Those looking for a bit of good news to start the week may have to cast the net further out. Stocks are tilting lower as COVID-19 cases flare up in China, threatening more lockdowns. And the plate was...

Turning Point Stock Doubles on Bristol Deal. What It Means for Biotech M&A.

Text size Photograph by Georges Gobet/AFP/Getty Images Turning Point Therapeutics stock has more than doubled after Bristol Myers Squibb announced that it had agreed to buy the company. It’s just the ...

I’m ‘Following Up’ on a Biotech Trade With Attractive Potential

Just before noon ET on Friday, May 27, Doug Kass posted the following in his Daily Diary on Real Money Pro:  “I added to SPDR S&P Biotech ETF (XBI)  this morning. And I sold some attractivel...

‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy

If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have stock-market capitalizations that are smaller th...

Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn’t Happening.

Text size Late last year, Barron’s predicted a wave of deals, citing biotech companies’ cash holdings. Above, the plates used to print one-dollar bills. Alex Wong/Getty Images With biotech...

AbbVie, Gilead and 4 Other Defensive Healthcare Stocks With Big Dividend Yields

Text size An AbbVie bio safety hood Courtesy of AbbVie Deep into the second quarter of the year, stocks have yet to recover, and investors are seeking safety in defensive plays. One sector that’s bene...

8 Biotech Stocks So Cheap That Their Technology Is Effectively Free

Text size A number of biotechs have market values that are less than the cash on their balance sheets. Dreamstime It’s mid-February, and the beleaguered biotech sector is showing no real signs of reco...

As stock-market turbulence revs up, this ETF theme has drawn 32% of flows in 2022 so far: ‘This isn’t a flash in the pan’

Thank god its Thursday! The Nasdaq Composite posted its first correction since March and equity benchmarks were trying to stage a mini rally, at last check on Thursday. Is this the beginning of the en...

Biotech Stocks Are Due to Bounce Back. This One Stands Out.

Text size Large-cap biotech will offer a smoother ride than small, and Vertex, in particular, looks attractive. Igor Akimov/Dreamstime.com Biotech stocks began the year in much the same way they ended...